Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Boundless Bio Inc. (BOLD)
NASDAQ:BOLD
Boundless Bio Inc. (BOLD) Stock Price & Analysis
7 Followers
BOLD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.94 - $15.24
Previous Close$10.09
Volume184.08K
Average Volume (3M)325.01K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$120.75M
Total Debt (Recent Filing)$2.19M
Price to Earnings (P/E)N/A
Beta0.81
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding22,239,333
10 Day Avg. Volume160,426
30 Day Avg. Volume325,009
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.86
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$23.00Price Target Upside129.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Ownership Overview
22.71% Insiders
0.00% Mutual Funds
0.26% Other Institutional Investors
77.03% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BOLD FAQ
What was Boundless Bio Inc.’s price range in the past 12 months?
Boundless Bio Inc. lowest stock price was $9.94 and its highest was $15.24 in the past 12 months.
What is Boundless Bio Inc.’s market cap?
Currently, no data Available
When is Boundless Bio Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Boundless Bio Inc.’s earnings last quarter?
Currently, no data Available
Is Boundless Bio Inc. overvalued?
According to Wall Street analysts Boundless Bio Inc.’s price is currently Undervalued.
Does Boundless Bio Inc. pay dividends?
Boundless Bio Inc. does not currently pay dividends.
What is Boundless Bio Inc.’s EPS estimate?
Boundless Bio Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Boundless Bio Inc. have?
Boundless Bio Inc. has 22,239,332 shares outstanding.
What happened to Boundless Bio Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Boundless Bio Inc.?
Currently, no hedge funds are holding shares in BOLD
---
Boundless Bio Inc. Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.00 (129.77% Upside)
$23.00 (129.77% Upside)
Insider Transactions
Bought Shares
Worth $14.6M over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
69.07%
Trailing 12-Months
Company Description
Boundless Bio Inc.
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
---
Technical Analysis
Best Analysts Covering BOLD
1 Year
1 Year Success Rate
0/0 ratings generated profit
1 Year Average Return
0.00%
initiated a buy rating 3 days ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of 0.00% per trade.
---